09 January 2012
EMA/638304/2008
Human Medicines Development and Evaluation

Paediatric Committee (PDCO)

Minutes of the 05-07 December 2012 meeting

Chair: Daniel Brasseur

I Introduction

I.1 Adoption of the minutes from previous meeting

Adopted

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.2 Adoption of the Agenda

Adopted with modifications

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.3 Declaration of Conflict of Interest

See Annex I

I.4 External attendance

Please refer to the December 2012 PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.5 Leaving/New Members and Alternates

Please refer to the December 2012 PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

II Opinions

II.1 Opinions on Products

II.2 Opinions on Compliance Check

II.3 Opinions on Modification of an Agreed Paediatric Investigation Plan

Please refer to the December 2012 PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

III Discussion of applications

The PDCO discussed 88 procedures in total[†], of which:

- 35 paediatric investigation plan applications;
- 14 product-specific waiver applications;
- 5 compliance check procedures (interim and final);
- 34 requests for modifications of an agreed paediatric investigation plan.

IV Nomination of Rapporteurs and Peer reviewers

• List of letters of intent received for submission of applications with start of procedure February 2013[1]for Nomination of Rapporteur and Peer reviewer • Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver	The PDCO approved the lists of Rapporteurs and Peer Reviewers.

V Update and finalisation of opinions and requests for modification

All opinions taken at this meeting (relating to adoption of opinions, recommendations, requests for modifications and applicability of class waivers) were made in the presence of the required quorum of members.

The opinions adopted during the Paediatric Committee meeting of December 2012 are published in the same month's meeting report published in the EMA website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab.

VI Discussion on the applicability of class waiver

Class waiver number	Active substance	Proposed indication	Condition	Outcome (confirmed / not confirmed)
EMEA-52-2012	RO5083945 (GA201)	Treatment of adenocarcinoma of the colon and rectum	Treatment of adenocarcinoma of the colon and rectum	confirmed

[†] The procedures discussed by the PDCO are on-going and therefore are considered confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Class waiver number	Active substance	Proposed indication	Condition	Outcome (confirmed / not confirmed)
EMEA-53-2012	RO5083945 (GA201)	Treatment of lung carcinoma (small cell and non-small cell carcinoma)	Treatment of lung carcinoma (small cell and non-small cell carcinoma	Confirmed
EMEA-54-2012	RO5083945 (GA201)	Treatment of oropharyngeal, laryngeal or nasal epithelial carcinoma (excluding nasopharyngeal carcinoma or lymphoepithelioma)	Treatment of oropharyngeal, laryngeal or nasal epithelial carcinoma (excluding nasopharyngeal carcinoma or lymphoepithelioma)	Confirmed
EMEA-55-2012	Pertuzumab (Perjeta)	Treatment, in combination with trastuzumab, fluorouracil (5 fluorouracil or capecitabine), and cisplatin, of patients with HER2-positive metastatic adenocarcinoma of the stomach and/or gastroesophageal junction who have not had prior treatment for metastatic disease	Treatment of gastric adenocarcinoma	Confirmed
EMEA-56-2012	Pertuzumab (Perjeta)	Treatment, in combination with standard chemotherapy, of recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expression	Treatment of ovarian carcinoma (excluding rhabdomyosarcoma and germ cell tumours)	Confirmed
EMEA-57-2012	RO5490254	Treatment of mesothelioma	Treatment of mesothelioma	Confirmed
EMEA-58-2012	RO5490254	Treatment of renal cell carcinoma	Treatment of kidney and renal pelvis carcinoma (excluding nephroblastoma, nephroblastomatosis, clear cell sarcoma, mesoblastic nephroma, renal medullary carcinoma and rhabdoid tumour of the kidney)	Confirmed
EMEA-59-2012	RO5490254	Treatment of endometrial carcinoma	Treatment of endometrial carcinoma	Confirmed
EMEA-60-2012	linsitinib	Treatment of non-small cell lung carcinoma	Treatment of lung carcinoma (small cell and non-small cell carcinoma)	Confirmed
EMEA-61-2012	linsitinib	Treatment of ovarian carcinoma (excluding rhabdomyosarcoma and germ cell tumours)	Treatment of ovarian carcinoma (excluding rhabdomyosarcoma and germ cell tumours)	Confirmed

Class waiver number	Active substance	Proposed indication	Condition	Outcome (confirmed / not confirmed)
EMEA-62-2012	Olaparib (AZD2281, KU-0059436)	Maintenance monotherapy for the treatment of patients with gBRCA mutation positive Platinum Sensitive Relapse (PSR) ovarian cancer who have responded (complete response or partial response) to platinum-based chemotherapy Maintenance monotherapy for the treatment of patients with gBRCA mutation positive first line ovarian cancer who have responded (complete response or partial response) to first-line platinum-based chemotherapy.	Treatment of ovarian carcinoma	Confirmed

VII Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

No requests were received for review during the December PDCO plenary.

VIII Other topics

Guidelines	
Proposal to EC on Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies	A proposal for changes* to the Guideline was adopted by the PDCO and forwarded to the European Commission.
Working groups	
Paediatric oncology	The product-related discussions were prepared and the draft model oncology PIPs* concerning rhabdomyosarcoma and acute myeloid leukaemia were discussed.
Paediatric inventory	Cardiovascular therapeutic area: Comments from public consultation were discussed and the final version of the list prepared.

	Infectious diseases: Comments on tropical diseases were discussed and the list was prepared for adoption for public consultation.
Formulation	No non-product related issues where reported to the Committee.
Non-Clinical	No non-product related issues where reported to the Committee.
Extrapolation	N/A
Other topics	
EC consultation on the Paediatric Regulation – feed-back on comments received	A representative of the European Commission, DG Health and Consumers, presented an initial feedback on the number and type of responses received during the public consultation on the Paediatric Regulation. The EC is preparing the Report[‡] for the European Parliament and the Council.
Reflection on revocation of the EMA decision on the list of class waivers	The PDCO continued with the review of the conditions that are covered by the class waiver. It was reflected how the evolution of science and of knowledge during the last years has challenged and changed the understanding of diseases and biological targets. The possibility was emphasised to waive classes of medicines which are likely to be unsafe; such a class waiver likely additionally refers to a condition or a specific use of the concerned class of medicine. The PDCO will continue the review of the class waiver and of the individual conditions covered by the class waiver.
Systematic review* of designs of dose-finding studies in Paediatric Investigation Plans (2010-2012)	The PDCO discussed with an external expert the types and features of those paediatric trials in agreed PIPs based on which doses (including dosing rules) for further trials or for a paediatric use are defined. It was discussed that some of these trials have the objective to compare different doses in children while others aim to validate the assumption that an extrapolated dose is appropriate. Further work is expected on this topic.
Annual reports on deferrals	Postponed to January 2013.
Development strategy for medicinal products targeting asthma in children*	The Committee agreed to put on hold this topic until the guideline is published for public consultation.
Overview of comments received on the concept paper on the involvement of Children and Young People	Postponed to January 2013.

[‡] Post meeting note: On 16 January 2013 the European Commission published in its website summary of the replies to our public consultation on the paediatric report as well as a copy of all replies receive:
http://ec.europa.eu/health/files/paediatrics/2013_pc_paediatrics/2013_paediatric_report_summary.pdf
http://ec.europa.eu/health/human-use/paediatric-medicines/developments/2013_paediatric_pc_en.htm

Inventory of paediatric medicines: Infectious diseases therapeutic area* Cardiovascular diseases therapeutic area	The inventory for the cardiovascular therapeutic area was adopted. The inventory for the therapeutic area of infectious diseases was adopted for public consultation.
Art. 5(3) on Propylene Glycol started by ED at request of PDCO in September 2011*	Postponed to January 2013
Model oncology PIPs	The PDCO adopted the model oncology PIP for rhabdomyosarcoma, which had been prepared by the PDCO with external experts in the Paediatric oncology task force of the EMA. This model PIP is suggested as a starting point for discussions on rhabdomyosarcoma development and on a PIP, rather than a template; the intention is to support pharmaceutical companies to take an initiative and to propose a PIP that is scientifically adapted to the respective medicine. The model oncology PIP for rhabdomyosarcoma will now be made public for consultation; it will be reviewed and updated as needed. The model oncology PIP for acute myeloid leukaemia will be discussed and possibly adopted at the January 2013 PDCO meeting.
PIP Application Summary*	The PDCO discussed and adopted a template for applicants to provide a structured, brief overview of their application for a Paediatric Investigation Plan. The PIP Application Summary will be part of a new template for the Scientific Document (parts B-E) that forms part of the submission for agreement of a PIP, for responding to the PDCO request for modification, and for requests for modification of an agreed PIP (the new template will be published in the guidance webpage: http://bit.ly/QwC2Gd).
Guideline on Clinical Medicinal Products Intended For The Treatment Of Pain*	The PDCO reviewed the latest comments incorporated into the draft guideline, and inserted them in the draft* for external consultation.

IX Any other business

Note on access to documents

Documents marked with an asterisk* in these minutes cannot be released at present as they are currently in draft format. They will become public when adopted in their final form.

Annex I to the Minutes of the PDCO of December2012

Documentation on Declaration of interest of members, alternates and experts

Based on the Declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of Committee members for the upcoming discussions.

In accordance with the Agency's revised Policy and Procedure on the handling of conflicts of interests, participants in this meeting were asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests).

Member, alternate, expert name	Outcome restriction following evaluation of electronic evaluation form	Topics on the current Committee Agenda for which this restriction applies
Michal Odermarsky	Restriction level XP	EMEA-000804-PIP01-09-M01
Matthias Keller	Restriction level DP	EMEA-000018-PIP01-07-M05
Matthias Keller	Restriction level DP	EMEA-000494-PIP01-08-M05
Matthias Keller	Restriction level DP	EMEA-000495-PIP01-08-M05
Matthias Keller	Restriction level DP	EMEA-000325-PIP01-08-M01
Matthias Keller	Restriction level DP	EMEA-000485-PIP01-08-M01
Matthias Keller	Restriction level DP	EMEA-000486-PIP01-08-M01
Peter Szitanyi	Restriction level DP	EMEA-001353-PIP01-12
Romaldas Maciulatis	Restriction level XR	EMEA-000726-PIP01-09-M01
Carine de Beaufort	Restriction level XR	EMEA-000128-PIP01-07-M05
Jaroslav Sterba	Restriction level XP	EMEA-001033-PIP02-11
Adriana Ceci	Restriction level XR	EMEA-000019-PIP08-12
Gerard Pons	Restriction level DP	EMEA-000019-PIP08-12
Matthias Keller	Restriction level DP	EMEA-001281-PIP01-12
Christoph Male	Restriction level DP	EMEA-001281-PIP01-12
Christoph Male	Restriction level XP	EMEA-000183-PIP02-12

Note: the procedures identified in the table above are on-going and therefore considered commercially confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

No new or additional conflicts were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting.

Restriction levels:

Evaluation of the conflict of interest	
Outcome	Impact
R-P	To be replaced for the discussions, final deliberations and voting as appropriate in relation to the relevant product or a competitor product.
XP	Where Individual product involvement is declared - PRODUCT INDICATION: - No involvement with respect to procedures involving the relevant product or a competitor product in the relevant indication i.e. no part in discussions, final deliberations and voting as appropriate as regards these medicinal products. - Cannot act as Rapporteur for these products - [Cannot act as Rapporteur for development of guidelines in concerned therapeutic area].
XC	Where cross product / general involvement is declared - COMPANY: - No involvement (as outlined above) with respect to products from the specified company. - Cannot act as Rapporteur for products from the relevant company(ies).
DP	Where Individual product involvement is declared - PRODUCT INDICATION: - Involvement in discussions only with respect to procedures involving the relevant product or a competitor product i.e. no part in final deliberations and voting as appropriate as regards these medicinal products. - Cannot act as Rapporteur for these products.
DC	Where cross product / general involvement is declared - COMPANY: - Involvement in discussions only with respect to products from the specified company. - Cannot act as Rapporteur on products from the relevant company(ies).
XR	Committee member cannot act as Rapporteur or Peer reviewer in relation to any medicinal product from the relevant company.
R-C	To be replaced for the discussions, final deliberations and voting as appropriate in relation to any medicinal product from the relevant company

Annex II to the Minutes of the PDCO of December 2012

List of Participants

Chair

Daniel BRASSEUR

Vice-chair

Dirk MENTZER

Members appointed by Member States or CHMP

Christoph MALE	Austria
Koenraad NORGA	Belgium
Dobrin KONSTANTINOV	Bulgaria
Jaroslav STERBA	Czech Republic
Marianne ORHOLM	Denmark
Irja LUTSAR	Estonia
Pirjo LAITINEN-PARKONNEN	Finland
Gerard PONS	France
Dirk MENTZER	Germany
Stefanos MANTAGOS	Greece
Agnes GYURASICS	Hungary
Gylfi OSKARSSON	Iceland
Kevin CONNOLLY	Ireland
Paolo ROSSI	Italy
Dina APELE-FREMIANE	Latvia
Carine de BEAUFORT	Luxembourg
Hendrik van den BERG	The Netherlands
Siri WANG	Norway
Marek MIGDAL	Poland
Helena FONSECA	Portugal
Vlasta KAKOSOVA	Slovak Republic
Janez JAZBEC	Slovenia

Fernando DE ANDRÉS TRELLES	Spain
Marta GRANSTRÖM	Sweden
Julia DUNNE	United Kingdom

Alternates appointed by Member States or CHMP

Karl Heinz HUEMER	Austria
Jacqueline CARLEER	Belgium
Peter SZITANYI	Czech Republic
Ann Marie KAUKONEN	Finland
Sylvie BENCHETRIT	France
Birka LEHMANN	Germany
Brian AYLWARD	Ireland
Francesca ROCCHI	Italy
Rugile PILVINIENE	Lithuania
Johannes TAMINIAU	The Netherlands
Ine Skottheim RUSTEN	Norway
Jolanda WITKOWSKA-OZOGOWSKA	Poland
Hugo TAVARES	Portugal
Dana Gabriela MARIN	Romania
Angeliki SIAPKARA	United Kingdom

Members representing patients' organisations

Alternates representing patients' organisations

Members representing health care professionals

Anthony James NUNN

Alternates representing health care professionals

Paolo PAOLUCCI

Experts

Peter BAUER	Medical statistician

Observers

Florian Schmidt	European Commission, Directorate General for Health

European Medicines Agency

Agnes SAINT RAYMOND	Head of Sector, Human Medicines Special Areas

Paolo TOMASI	Head of Section, Paediatric Medicines
Sophie OLIVIER	Scientific Administrator, Paediatric Medicines
Anne-Sophie HENRY-EUDE	Scientific Administrator, Paediatric Medicines
Almudena SAIZ HERRANZ	Scientific Administrator, Paediatric Medicines
Benjamin PELLE	Scientific Administrator, Paediatric Medicines
Cecile OLLIVIER	Scientific Administrator, Paediatric Medicines
Dobromir PENKOV	Scientific Administrator, Paediatric Medicines
Elin Haf DAVIES	Scientific Administrator, Paediatric Medicines
Giovanni LESA	Scientific Administrator, Paediatric Medicines
Gunter EGGER	Scientific Administrator, Paediatric Medicines
Irmgard EICHLER	Scientific Administrator, Paediatric Medicines
Janina KARRES	Scientific Administrator, Paediatric Medicines
Peter KÁROLYI	Scientific Administrator, Paediatric Medicines
Ralf HEROLD	Scientific Administrator, Paediatric Medicines
Ralph BAX	Scientific Administrator, Paediatric Medicines
Richard VESELY	Scientific Administrator, Paediatric Medicines
Thorsten OLSKI	Scientific Administrator, Paediatric Medicines
Chrissi PALLIDIS	Scientific Administrator, Paediatric Medicines
Alessandro JENKNER	National Expert on Secondment, Paediatric Medicines
Cristina BEJNARIU	Trainee
Aurelie HERVIEU	Assistant, Paediatric Medicines
Isabel PEREZ	Assistant, Paediatric Medicines
Anna MESTERHAZY	Assistant, Paediatric Medicines